Taken together, these results suggest that delivery of a WT version of AGBL5 or reducing expression of TTLL5 could be a potential therapy for patients with RP associated with mutations in AGBL5. Delivery using AAV has been widely studied, but the main limitation of AAV lies in their capacity to carry approximately 5 kb of genetic material [59]. This evidence concerns the gene AGBL5 and retinitis pigmentosa 1.